The efficient gene transfer of immunostimulatory cytokines into autologous tumor cells or the transfer of tumor-associated antigens into professional antigen-presenting cells is a prerequisite for many immunotherapeutic approaches. In particular with B cells, the efficiency of gene uptake is one of the limiting factors in cell-based vaccine strategies, since normal and malignant human B cells are commonly refractory to transducing gene vectors. Due to its natural tropism for human B cells, Epstein-Barr virus (EBV), a human herpes virus, might be an option, which we wanted to explore. EBV efficiently infects human B cells and establishes a latent infection, while the viral genome is maintained extrachromosomally. Although these characteristics are attractive, EBV is an oncogenic virus. Here, we present a novel EBV-derived vector, which lacks three EBV genes including two viral oncogenes and an essential lytic gene, and encodes granulocyte-macrophage colony-stimulating factor (GM-CSF) as a cytokine of therapeutic interest. We could show that EBV vectors efficiently transduce different B-cell lines, primary resting B cells, and tumor cells of B-cell lineage. Vectorderived GM-CSF was expressed in sufficient amounts to support the maturation of dendritic cells and their presentation of model antigens to cognate T-cell clones in autologous settings and an allogeneic, HLA-matched assay. We conclude that the EBV vector system might offer an option for ex vivo manipulation of B cells and gene therapy of B-cell lymphomas. Gene Therapy (2006) 13, 150-162.
Introduction
Immune therapy of human cancers includes the concept of active immunization using cytokine gene-modified tumor vaccines. Induction of a potent systemic immune response in animal models as well as in clinical trials supports the view that such cellular vaccines warrant further investigation as potential therapeutic tools (for a recent review, see Pardoll 1 ). Since the application of gene-modified cellular vaccines requires efficient gene transfer into human tumor cells, viral vectors are widely used to introduce foreign genetic information. In particular, recombinant adenovirus, adeno-associated virus, and retroviruses have been used in order to transduce many different types of human target cells. 2 There are also several reports that demonstrate a gene transfer into human tumor B cells (Rieger and Kipps, 3 Kofler et al. 4 and references therein), but the low transduction rates and the need to stimulate the target cells to survive and express the transgene in vitro are obvious limitations. Mostly, B cells are even refractory to transduction with viral and nonviral gene vectors. As Epstein-Barr virus (EBV), a member of the herpes virus family, has a natural tropism for B cells, it seems to be an ideal vehicle to transduce resting or proliferating human B cells. EBV genomes and EBV-derived vectors are maintained extrachromosomally. As a consequence, they do not cause potential additional problems such as random integration into the host chromosome. Following infection, the viral vector genome can sustain long-term persistence, which might equal long-term transgene expression. Since EBV is associated with a number of human malignancies and was consequently categorized as a type 1 carcinogen, 5 the EBV genome requires intensive genetic engineering and safety testing prior to its application as a gene delivery vector in experimental human therapies.
Here we present a first step towards the development of safe and B-cell-specific gene vectors on the basis of EBV. Three genes were deleted, which either rank as known or potential oncogenes or as the main regulator and initiator of EBV's lytic phase. LMP1 and EBNA2 were removed since they are critically involved in in vitro growth transformation of primary B cells. A virus lacking both genes does not support growth transformation of primary human B cells in vitro. 6, 7 The inactivation of the third EBV gene, BZLF1, leads to a single-cycle EBV vector that is infectious but cannot spread to other cells because its lytic program is blocked both in terms of transactivation of essential viral lytic genes 8 and activation of the lytic origin of DNA replication of EBV. 9 The modified vector genomes still encode all viral genes (but BZLF1), which are essential and sufficient for virus production. Thus, 293HEK cells, which carry the vector genome in a stable and latent manner, support autonomous gene vector packaging upon transient transfection of a BZLF1 expression plasmid to induce EBV's lytic phase as described. 10 As a therapeutic model transgene, the granulocytemacrophage colony-stimulating factor (GM-CSF) gene was introduced into this triple knockout EBV vector. GM-CSF modulates proliferation and differentiation of hematopoietic cells 11 and has been shown to be a very potent immunostimulatory cytokine that enhances antitumor immunity. 12 Dendritic cells (DCs) are the most potent professional antigen-presenting cells (APC) with characteristics such as efficient antigen uptake, processing and presentation of both exogenous and endo genous antigens, and DCs are also the main targets of GM-CSF. Recent insights into DC biology have underscored their importance in stimulating antitumor B-and T-cell immunity. 13 GM-CSF promotes the differentiation of DCs and leads to enhanced phagocytosis of, for example apoptotic tumor cells and improved expression of costimulatory molecules.
14 Clinical studies employing autologous tumor cells transduced ex vivo to secrete GM-CSF report on the successful vaccination against renal cell carcinoma, 15 melanoma [16] [17] [18] and non-small-cell lung cancer. 19 We show here that EBV-based vectors are suitable for transferring the GM-CSF gene into human B cells, including established B-cell lines, resting primary B cells, and tumor B cells from patients with B-cell chronic lymphocytic leukemia (B-CLL). Furthermore, we show that GM-CSF expressed from EBV-based vectors in transduced human B cells is biologically active and stimulates immune responses.
Results

GM-CSF expressing EBV vectors
Previously, we reported on the cloning of the complete EBV genome of the prototype EBV strain B95.8 onto an F factor-based plasmid. 10 This plasmid termed maxi-EBV is approximately 180 kbp in size and accessible to genetic manipulation in Escherichia coli. 20, 21 The GM-CSF-EBV vectors used in this study are based on the maxi-EBV technology. 21 Three major EBV genes (LMP1, EBNA2, and BZLF1) were deleted by homologous recombination to meet the safety aspects for a prospective application in gene therapy (Figure 1a) . The latent EBV gene LMP1 is considered to be essential for in vitro growth transformation of B lymphocytes by EBV, 22, 23 and is critically involved in the efficiency of this process. 7, 24 In addition, LMP1 scores as a potential oncogene. [25] [26] [27] EBNA2 is essential for growth transformation of B lymphocytes 6, 28 and acts as a coactivator of the viral genes LMP1, LMP2A, the viral Cp promoter, and cellular genes such as c-fgr and c-myc (for a recent review, see Kieff and Rickinson 22 ). The third gene deleted on the EBV vector is BZLF1, which acts as the key transactivator and molecular switch of virus production. BZLF1 is essential for the lytic program of the virus because it activates essential lytic genes 8 and the lytic origin of DNA replication of EBV. 9 As a consequence, the triple knockout
À EBV vector is incapable of transforming B cells (data not shown), but can infect B cells efficiently as a single-cycle virus.
The two GM-CSF-EBV vectors in this study differ with respect to the insertion site of the transgene and the expression strategy (Figure 1a) . In both cases, the GM-CSF gene is under the control of the cytomegalovirus (CMV) promoter and both GM-CSF-EBV vectors encode GFP as phenotypic marker. The EBV vector 2698 carries the GM-CSF gene in conjunction with the rabbit b-globin intron and the human b-globin enhancer, 29 which were inserted into the viral BZFL1 locus. In contrast, 2660 carries a bicistronic expression cassette encoding GFP and GM-CSF cloned into a prokaryotic F-factor backbone ( Figure 1a) . In addition, a triple knockout
À EBV vector termed 2575 lacking GM-CSF was used as a control (Figure 1a) . The EBV vectors used in this study are compiled in Table 1 . The three EBV vector constructs were stably introduced into 293HEK cells in which they acquire an latent state, in which the EBV genomes are maintained as extrachromosomal plasmids at a low copy number (Delecluse et al.
10
; data not shown). Gene vector production was initiated by transient transfection of expression plasmids encoding the viral genes BZLF1 20 and BALF4. 30 The gene vectors were purified and concentrated by ultracentrifugation, and the viral titer was quantified after Raji cell infection according to the number of GFP-positive cells. The titers could be upscaled to reach 1 Â 10 6 green Raji unit (GRU)/ ml. 7 Since Raji cells, an established human EBV-positive B-cell line, are readily infectable with EBV and not adversely affected by superinfection, they allow the quantitation of biologically active, infectious EBV particles, which successfully transduce the GFP gene. This is a fast and practical approach with known limitations. In line with earlier experiments, 31 infection of Raji cells underestimates the concentration of infectious particles by a factor of about 10, as revealed by infecting human B blast target cells with GFP-titrated wild-type maxi-EBV 2089 stocks 10 in in vitro growth-transformation experiments (Altmann and Hammerschmidt, submitted). Since such experiments cannot be performed with the transformation-incompetent LMP1
À
/EBNA2
À EBV vectors of this study, we used the GFP-based method for a rough quantification of infectious viral particles. 
To examine the infection efficiency and expression levels of GM-CSF quantitatively, Raji cells were transduced with GM-CSF-EBV vectors and the supernatants were analyzed for the release of the gene product by ELISA. To this end, 4 Â 10 5 Raji cells were transduced with the GM-CSF-EBV vector 2660 or 2698 at an MOI of 0.3 GRU. At 24 h after addition of the gene vector stocks, the cells were washed to dispose of any carryover of GM-CSF, which might have contaminated the gene vector preparation. After 4 h, an aliquot of the supernatant was collected for the analysis of residual GM-CSF levels. Culture supernatants were harvested 2, 4, and 6 days after transduction and analyzed for GM-CSF production by ELISA (Figure 2a ). The accumulation of the transgene product steadily increased for at least 1 week and secretion levels of up to 10 ng/1 Â 10 6 cells/24 h could be achieved. Using transduced Raji cells, longer secretion periods of up to 2 weeks are possible (data not shown). Other B-cell lines like BJAB, Akata27, an EBV-negative derivative of Akata cells, 33 and DG75 34 could also be transduced very efficiently ( Figure 2b Table 2 ) as measured by GFP expression, which was comparable to infections with wild-type 2089 EBV. The A prokaryotic F-factor mini-replicon was inserted into the B95.8 wild-type EBV genome for genetic modification in E. coli. Together with the F-factor fragment, a GFP expression cassette and the gene for hygromycin resistance (hyg) as phenotypic and selectable markers, respectively, were inserted to monitor transduction rates and facilitate the generation of stable cell lines. Three major EBV genes (LMP1, EBNA2, BZLF1) were deleted from the cloned wild-type EBV genome. This triple knockout EBV genome 2575 resulted in a nontransforming viral gene vector with decreased pathogenic potential. Expression cassettes coding for the GM-CSF gene were inserted into the BZLF1 gene locus as in the EBV vector 2698 or upstream of GFP within the prokaryotic backbone as in the EBV vector 2660. In all cases, the GM-CSF gene is expressed from the CMV promoter. Additional cis-acting elements such as the b-globin enhancer, the IRES and introns are schematically indicated. (b) Expression of vector-derived GM-CSF in Raji cells. 4 Â 10 5 Raji cells were transduced with the GM-CSF-EBV vector 2660 (MOI 0.6 GRU). After 3 days, Brefeldin A (3 mg/ml) was added for 17 h to the culture medium to block secretion of GM-CSF. Whole-protein cell lysates (c) or cell culture supernatants of nontransduced (mock) or GM-CSF-EBV vectortransduced (2660) Raji cells with (+) or without (À) Brefeldin A treatment were analyzed by Western blotting using an aGM-CSF antibody. The broad smeary band is due to heavy glycosylation of GM-CSF in Raji and 293HEK cells. Nontransduced Raji cells do not express GM-CSF. As a positive control, whole-protein lysates of 293HEK cells were analyzed, which had been transiently transfected with an expression plasmid for GM-CSF (GM-CSF/pRK5) and treated with Brefeldin A to block protein transport on day 3 after DNA transfection.
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efficiency of vector transduction with B-CLL cells mainly depended on the vitality of the very fragile tumor cells in the ex vivo setting and varied considerably from patient to patient (data not shown). Since EBV exclusively infects B cells in vitro, GFP-positive cells were also CD19+, indicative of EBV's B-cell tropism (data not shown). We did not determine the copy number in the transduced cells since we performed short-term experiments only. As we used a low MOI (0.5 transducing units in the experiments shown in Table 2 ), we are certain that the fraction of cells which showed transgene expression (GFP or GM-CSF) carried only one and, in rare instances, very few vector genomes.
In the EBV vector 2660, GFP and GM-CSF are expressed from a bicistronic mRNA. Whereas GM-CSF is the upstream gene, GFP is under the translational control of an internal ribosomal entry site (IRES) cisacting element ( Figure 1a ). Therefore, the expression level of GFP might underestimate the transduction efficiency of the 2660 gene vector. However, the efficiency of GM-CSF expression was found to be higher with the EBV vector 2698 in which both GM-CSF and GFP are independently expressed from monocistronic mRNAs. With vector-transduced B-CLL cells, we estimate that the successfully transduced, GFP-positive cell hardly carries more than one vector genome on the average, given an initial MOI of 0.5. Still, the GM-CSF secretion rates of B-CLL cells with the 2698 vector were in the range of about 1 ng/1 Â 10 6 cells/24 h 3 days after transduction ( Figure  2b ). The analysis indicated that this new type of EBV vector is suitable for transducing different human B cells at moderate to low MOI. Even B-CLL tumor cells that do not proliferate and are very difficult to maintain ex vivo could be easily transduced in the absence of additional stimuli. In contrast to other viral vectors, EBV and EBVderived vectors transduce B lymphocytes primarily via the B-cell-specific CD21 receptor, which appears to efficiently support gene delivery into human B cells.
Vector-derived GM-CSF is functional
GM-CSF in supernatants from transduced primary B lymphocytes, Raji, and B-CLL cells was tested for its biological activity in a cell proliferation assay using TF-1 cells whose continuous proliferation depends on exogenously added cytokines. 35 For this purpose, supernatants were serially diluted and incubated with 5 Â 10 To further assess the functional significance of EBV vector-derived GM-CSF, we studied its effect on the maturation process of DCs in vitro. We generated DCs by incubation of monocytic precursor cells with GM-CSF supernatants derived from GM-CSF-EBV vector-transduced cells. As a source of human monocytes, we used freshly prepared PBMCs isolated via Ficoll gradient centrifugation from the peripheral blood of healthy donors. After plastic adherence on IgG-coated Petri dishes, monocytes were cultivated for 6 days with equal concentrations of GM-CSF derived from supernatants from GM-CSF-EBV vector-transduced Raji cells or exogenously added recombinant GM-CSF as a control. Several DC differentiation assays were analyzed in parallel using supernatants from Raji cells transduced with the vector 2698 or 2089 wild-type EBV, nontransduced Raji cells, and nontransduced Raji cells in combination with recombinant GM-CSF. After 6 days of differentiation, the immature DCs were incubated for another 24 h with TNF-a, IL-1b, and PGE 2 for final maturation. In the wells containing GM-CSF, cells showed the characteristic phenotype of DCs and a considerable increase in size. In control wells without GM-CSF, some DCs developed spontaneously, but mainly monocytes were generated. Flow cytometry analysis of CD83 (upregulated during maturation of DCs) and CD14 expression (lost upon DC differentiation) was performed after 7 days. Expression of CD83 considerably increased in the presence of GM-CSF, whereas CD14 expression markedly decreased as expected in cells incubated with GM-CSF-containing supernatants as shown in Figure 4a . The levels of expression of the costimulatory molecule CD80 increased only slightly. With regard to all surface molecules examined, vector-produced and recombinant GM-CSF exhibited comparable or identical effects. Additional relevant DC immunophenotypic markers like CD86 and MHCII only showed minor differences (data not shown).
The effect of vector-produced GM-CSF on the endocytotic ability of DCs was assessed after 6 days of DC Interestingly, DCs that had been differentiated with gene-vector-produced GM-CSF displayed the highest FITC-dextran uptake, which was even higher than after differentiation with exogenously added recombinant GM-CSF.
DCs differentiated with vector-derived GM-CSF stimulate T cells
We performed functional assays to evaluate the immunostimulatory capacity of DCs which were differentiated with gene-vector-produced GM-CSF. After 7 days of DC differentiation, the capacity for HLA-restricted presentation of the model antigen neomycin phosphotransferase was evaluated by determining the cytokine secretion of an antigen-specific CD4 + T-cell clone. 36 HLA-matched DC-precursor cells were incubated with gene vectorderived GM-CSF from transduced Raji cells or control supernatants and IL-4 as described before. Immature DCs were used for this experiment as they take up and process antigens most efficiently via phagocytosis. 37 For final maturation, the immature DCs were plated in medium with TNF-a, IL-1b, and PGE 2 , and loaded with the model antigen neomycin phosphotransferase in different concentrations. After 24 h, irradiated DCs were cocultivated with 1 Â 10 5 neomycin-specific CD4 + cells. After 17 h, the release of GM-CSF could be quantified by ELISA (Figure 4c ). In previous studies using this T-cell clone, GM-CSF secretion was found to be the most significant marker for T-cell activation. 36 As a positive control, a DP3-expressing lymphoblastoid cell line (LCL1.11) was loaded with the antigen (Figure 4c ; gray closed bar). The results demonstrated that both the genevector-derived GM-CSF (black bar) and the exogenously added, recombinant cytokine (hatched bar) had the same effect on differentiation of DC precursor cells. In agreement with the phenotypic data (Figure 4a ), genevector-produced GM-CSF provides full differentiation capacity and leads to the development of T-cell-activating DCs.
EBV-GM-CSF vector transduction of B cells promotes improved T-cell responses in an autologous setting
To evaluate the capacity of the GM-CSF-producing EBV vectors in a situation that might be clinically more relevant, we tested the vectors in an autologous setting with PBMCs of healthy donors. A sketch of the experiment is outlined in Figure 5a . PBMCs were purified through Ficoll gradient centrifugation and the CD19 + cells were isolated with anti-CD19 magnetic beads to a purity of about 96%. The CD19-depleted PBMCs were viably frozen in liquid nitrogen. Immediately after purification, 5 Â 10 5 CD19 + cells were transduced with the GM-CSF-EBV vector 2698 or the control vector 2575 (Figure 1a (a) Monocyte-derived DCs from peripheral blood were generated by incubation with vector-derived GM-CSF from transduced Raji cells and IL-4. Supernatants of different transduction approaches were used -wild-type-EBV-infected Raji cells, nontransduced Raji cells, nontransduced Raji cells in conjunction with recombinant GM-CSF (800 U/ml), and 2698 GM-CSF-EBV vector-transduced cells. After 6 days of culture, TNF-a, PGE 2 , and IL-1b were added to promote final maturation of DCs. Flow cytometry analysis showed the differently maturated DC populations after costaining with aCD14-, aCD83-, and aCD86-antibodies. The MFI indicates the surface expression of these markers. (b) DCs maturated with gene vectorderived GM-CSF show high endocytotic activity. Plastic-adherent monocytes from peripheral blood were incubated for 6 days with genevector-derived GM-CSF and IL-4. Endocytotic activity was measured by FITC-Dextran uptake for 30 min. The MFI shown in the diagram represents the FITC-dextran uptake at 371C after subtracting the background at 41C. DCs treated with gene vector-derived GM-CSF showed the highest endocytotic activity, exceeding the effects seen with recombinant GM-CSF. As a control, supernatants of nontransduced Raji cells were used. Shown are the means and standard deviations from three independent experiments. (c) DCs maturated with gene vector-derived GM-CSF can efficiently present antigen and activate a specific T-cell clone. After 4 days of maturation with gene vector-derived or recombinant GM-CSF and IL-4, the differently treated DC precursor cells were loaded with various concentrations of the model antigen neomycin-phosphotransferase for 24 h and incubated with TNF-a, PGE 2 , and IL-1b for final differentiation. After washing cells the next day, DCs were coincubated with an HLA-matched CD4-positive T-cell clone for another 24 h. T-cell activation was measured by determining the cytokine release (GM-CSF) of the neomycin-specific T cells by quantitative ELISA. Four different DC maturation approaches were included into the experiment. DCs were incubated either with supernatants of nontransduced Raji cells (i), wild-type EBV-infected Raji cells (ii), nontransduced Raji cells and recombinant GM-CSF (800 U/ml) (iii), or GM-CSF-EBV vector-transduced cell supernatant (iv). As a negative control, DCs were used without antigen loading. As a positive control, a DP3-positive lymphoblastoid B-cell line (LCL) was used to present the antigen to the T-cell clone. One representative out of three experiments is shown. 
Discussion
In the field of gene and immune therapy, there is still the need for the development of efficient methods to transfer therapeutic genes into primary target cells. The most widely applied vectors are recombinant retroviral and adenoviral vectors. 2 The major drawback of retroviral vectors is their integration into the genome of the targeted cells. Retroviral integration as such can be harmful 38 and needs to be monitored in a human situation. 39 Adenoviral vectors, on the other hand, have caused some major problems concerning acute immune reactions against viral proteins 40 and do not maintain a long-term expression unless combined with additional episomal functions. 41 Immune therapy with human B cells in particular is an ambitious goal, since these cells are mostly refractory to the uptake of DNA-based vectors as well as viral vectors. Viral vectors have been employed by several groups for the transduction of primary B cells, but relevant transduction rates could only be achieved with high MOIs or with additional stimulation of the target B cells (for recent examples, see Wendtner et al., 42 Wierda et al., 43 Janssens et al., 44 Bonamino et al., 45 and Lizee et al. 46 ). In this study, we developed and tested a second generation of large, This second generation of EBV-derived vectors, which can express an immunostimulatory cytokine, has EBV's unique B-cell specificity, and is especially interesting for the genetic engineering of antigen-presenting B cells or immune therapy of B-cell malignancies. As our titering method probably underestimates the concentration of biologically active, transducing vector particles by a factor of about 10, relative low MOIs of 0.3-1 GRU led to transduction rates of up to 70% of the targeted cell population depending on the origin of the B cells. Therefore, the necessary virus load can be reduced, which might be beneficial for ex vivo manipulation of sensitive tumor cells. Moreover, even wild-type EBV does not involve a risk to the infected cells since it establishes a latent infection as a rule 22 and protects the infected primary B cells from spontaneous apoptosis. 47 Long-term persistence of transgene expression is supported by the extrachromosomal maintenance of the EBV vector genome, which is retained in the nucleus and protected from degradation in resting, nonproliferating cells and capable of self-replicating in dividing cells (for a recent review and references therein, see Conese et al. 48 and references therein). These characteristic features support the prolonged expression of the gene(s) of interest in EBV vector-transduced cells. Our study also indicates that GM-CSF transgene expression is maintained in the absence of selective pressure over 8 days (Figure 2 ) up to a period of 14 days depending on the cell type (data not shown), which is in line with numerous reports on episomally maintained vector systems. 48 We demonstrate in this study that the expression of the transgene GM-CSF could reach up to 10 ng/10 6 cells/ 24 h, depending on the B-cell type. These levels were lower compared to published data on retroviral and adenoviral vectors, 17, 49 and were especially low in B-CLL leukemia cells (Figure 2) . However, for retro-and adenoviral vectors, expression levels considerably varied from cell line to cell line. It was also shown that even minute levels of GM-CSF expression are sufficient to induce effective tumor protection in in vivo model systems, 50, 51 which makes GM-CSF one of the most potent immunostimulatory reagents in gene therapy. In melanoma models, GM-CSF evoked highest levels of costimulatory molecules on DCs, indicative of greatly improved functional maturation. This enhanced activity was interpreted to promote the infiltration of large numbers of T cells. 52 Furthermore, the development of a specific antitumor response could be observed. 12 In a clinical setting, immunotherapy with GM-CSF genemodified tumor cells has also been evaluated. 49 To our knowledge, B-cell lymphomas with the exception of B-CLL cells have been transduced with GM-CSF and used as cellular vaccines to induce systemic antitumor effects, 50, 53 indicating that GM-CSF is beneficial in certain malignancies in which relevant tumorassociated antigens are commonly not known. GM-CSF in our study ranks as a model cytokine demonstrating the efficient, B-cell-specific gene transfer of a potent immunostimulatory gene in conjunction with novel EBV vectors, which underscores the feasibility and proof of our concept. B-CLL tumor cells are particularly challenging target cells in vector-mediated gene transfer because these cells are nondividing and have a very limited life span ex vivo. Even infection with wild-type EBV does not rescue these tumor B cells from spontaneous or activation-induced apoptosis, although they can be readily infected with this virus. 54, 55 Activation of B-CLL cells via their endogenous surface CD40 or B-cell receptors or incubation with CpG-oligodeoxynucleotides partially overcomes this hurdle and improves the transduction rates of recombinant adeno or AAV-based gene vectors, but constitutes an additional manipulatory step (for a recent review, see Wendtner et al.
42
). For these reasons, it was interesting to learn whether EBV-based gene vectors might be effective using B-CLL cells in an ex vivo situation.
We showed that supernatants of GM-CSF-EBV vectortransduced B cells can support and improve maturation of DCs (Figure 4) . In T-cell stimulation assays, in which DCs were maturated with vector-derived GM-CSF and incubated with antigen-specific T cells, the antigen was efficiently presented. Even in approaches using peripheral primary monocytic cells, our experiments clearly indicated that vector-mediated transfer of GM-CSF into the fraction of target B cells led to an enhanced T-cell response ( Figure 5 ). We do not know the antigen(s) against which this marked T-cell response is directed. Although we cannot exclude an autoreactive effect in experiments shown in, for example, Figure 5 , an EBVdirected response is more likely since our donors had EBV-specific T cells. We assume that this T-cell response is mainly directed against the viral vector particlesderived antigens because extensive de novo expression of viral genes in vector-transduced cells is unlikely in the absence of both viral key transactivators, EBNA2 and BZLF1. However, we cannot exclude minute and transient expression of certain EBV genes, which are found expressed immediately after infection of primary B lymphocytes only (Altmann and Hammerschmidt, submitted). Although additional deletions of dispensable viral genes are technically feasible, the deletion of three critical key genes, EBNA2, LMP1, and BZLF1, involved in EBV-mediated transformation or potential spread of the viral vector complies with some of the major safety prerequisites. Small EBV-based vectors, which lack any viral gene and therefore minimize the immunological presentation of viral epitopes, are under construction, as well as a novel packaging cell line based on our previous approach. 20 The results reported in this paper indicate the potential of this new EBV vector system for the production of autologous tumor cell vaccines. For instance, this vaccine might hold promise as adjuvant therapy for the treatment of patients with B-CLL. The advantage of complete cell vaccines as compared to tumor-specific proteins or peptides is that an autologous tumor cell vaccine contains the complete repertoire of tumor-associated antigens, which are present in the tumor. In the case of B-CLL, little is known about tumor-associated, immunologically relevant antigens. B-CLL is the most common leukemia in the Western world and largely refractory to conventional therapies. Gene transfer of immunostimulatory GM-CSF could be an adjuvant experimental approach to potentiate immune responses against leukemic cells. As the EBV vector system in this and a previous study 42 is capable of efficiently transducing B-CLL tumor cells, this approach 
Materials and methods
Construction of recombinant GM-CSF-EBV vectors
To generate two GM-CSF-EBV vectors and one control vector in the context of a modified EBV genome, a triple knockout (LMP1
À ) was constructed on the basis of the wild-type B95.8 EBV strain cloned onto the F-factor plasmid p2089. 10 The first deletion was carried out by the aid of a pST76-amp-based shuttle plasmid 57 containing the deleted EBNA2 open reading frame flanked by homologous EBV sequences (p2419). A cointegrate of the shuttle plasmid and the p2089 EBV plasmid was formed with the 'chromosomal building' technique, 58 which led to the EBNA2 À -EBV construct p2491 after routine genetic manipulations. Details are available upon request. In order to inactivate LMP1, the same technique was used again with a second temperature-sensitive pST76-amp shuttle plasmid to introduce the Daa 22-212 LMP1 mutant allele into the LMP1 locus 7 of p2491 to yield the EBNA2 À
/LMP1
À double knockout EBV genome p2510. In order to inactivate the BZLF1 gene, the plasmid p2088 was constructed, which contains EBV sequences with the BZFL1 locus into which the kanamycin phosphotransferase gene from pCP15 59 flanked by two FRT sites was inserted to delete exons 1 and 2 of BZFL1. A linearized fragment derived from the p2088 targeting plasmid was used for homologous recombination with p2510. As the selectable marker gene is flanked by FRT sites, it could be excised from the maxi-EBV genome by transient expression of FLP in E. coli 59 to yield the triple knockout control vector 2575 ( Figure 1 , Table 1 ). To generate the first GM-CSF-EBV vector p2698 (Figure 1) , the XbaI/HindIII fragment of the expression plasmid BCMGS 29 with the open reading frame of the human GM-CSF gene (Figure 1 ) was cloned onto p2088, the BZLF1 targeting plasmid. With this strategy, the deletion of the BZLF1 gene and insertion of the GM-CSF gene could be achieved in one step on the basis of the double knockout EBNA2 À
À EBV genome p2510 (Table 1 ). The second GM-CSF-EBV vector p2660 contains the GM-CSF expression cassette in the prokaryotic plasmid backbone as shown in Figure 1 . On the basis of an IRES-EGFP expression plasmid (Clontech), the open reading frame of the GM-CSF gene was cloned immediately downstream of the human CMV enhancer/promoter. This bicistronic expression cassette was inserted together with a kanamycin resistance gene from pCP15 into the p1919 plasmid, 10 which encompasses the bacterial F-factor backbone of the maxi-EBV plasmid p2089. 10 A fragment of this p1919-based targeting construct was used to introduce the GM-CSF expression cassette into the F-factor backbone of p2575 to yield the GM-CSF-EBV vector p2660. To promote the integration of linear DNA fragments in the DH10B E. coli host, the conditional recA/redg expression plasmid p2650 on the basis of pST76-amp was employed and recombinants were selected with a combination of 30 mg/ml chloramphenicol and 30 mg/ml kanamycin as described. 7 DNAs of several colonies were analyzed with restriction enzyme analysis. The genetic composition of the modified EBV genomes was verified by restriction enzyme analysis, Southern blot hybridization, and partial DNA sequencing.
Preparation of infectious viral vector stocks
On the basis of 293HEK cells, stable cell lines were established after individual transfection of the three EBV vector DNAs (p2575, p2660, p2698) and selection with hygromycin as described. 7 To obtain gene vector stocks, the cell lines were transiently transfected with expression plasmids encoding BZLF1 60 and BALF4 30 to induce EBV's lytic cycle. At 72 h post-infection, supernatants were harvested and filtered through 1.2-mm pore filters. Viral vector supernatants were purified and concentrated through ultracentrifugation at 40 000 g at 41C for 5 h. Virus vector sediments were resuspended in about 10% of the original volume in HBSS buffer and stored at 41C.
Infection of Raji cells and primary B cells, definition of GRUs
The three different EBV vector stocks were quantified after infection of Raji cells as described. 7, 30 Briefly, 3 Â 10 5
Raji cells were incubated at 371C in 24-well cluster plates with different dilutions of the virus stocks to be analyzed. The absolute number of GFP-positive cells was determined by UV microscopy in a defined fraction of the total Raji cell population 3 days after infection. On the basis of these data, GRUs/ml were calculated as a measure of the concentrations of infectious maxi-EBV particles in different virus stocks. Human B-cell lines and primary human B lymphocytes were infected with different dilutions of the adjusted vector stocks as described in detail in the Results section.
Preparation of primary cells
Peripheral blood was obtained from healthy individuals and patients after informed consent. Blood samples of 10 different B-CLL patients were included in this study, eight of which could be successfully transduced. As representative examples, results with three and six B-CLL samples are shown in Figure 2b and Table 1 , respectively. Primary B cells from adenoids of healthy children were isolated as described before. 7 PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation and suspended in RPMI 1640 (Life Technology) supplemented with 10% autologous heat-inactivated and pooled human serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin prior to infection with the different GM-CSF-EBV vectors. CD19 + B cells were enriched by MACS columns (Miltenyi Biotech).
Western blot analysis
GM-CSF protein was extracted and analyzed as described. 61 For detection of human GM-CSF, a polyclonal rabbit antibody (Chemicon) was used. Immunoblots were developed using peroxidase-coupled secondary antibodies (Promega) and ECL reagent (AmershamPharmacia).
DCs and T-cell clones
DCs obtained from healthy donors were matched regarding the HLA phenotype of the corresponding DP3-restricted T-cell clone. After Ficoll-Hypaque Epstein-Barr virus vector-mediated gene transfer E Hellebrand et al density-gradient centrifugation, PBMCs were plated on Falcon dishes precoated with a human g-immunoglobin solution (1 mg/ml in PBS). After 30 min of adherence, myelomonocytic precursor cells were washed and incubated with IL-4 (500 U/ml PAN Biotech) and recombinant GM-CSF (800 U/ml Leukomax s , essex) or equivalent amounts of EBV vector-produced GM-CSF in RPMI 1640 medium complemented with 1% autologous inactivated human serum. At day 6, immature DCs were washed and plated for antigen loading (neomycin phosphotransferase II, 200 ng/ml titrated) and for subsequent incubation with the HLA-matched-antigen specific T-cell clone at 1 Â 10 4 cells in medium with TNF-a (2.5 ng/ml, PAN Biotech), PGE 2 (0.5 mg/ml, Sigma), and IL-1b (2 ng/ml, PAN Biotech). The CD4 + T-cell clone used in Figure 4c is DP3-restricted and reacts against an epitope (AS 216-229 DRYQDIALATRDIA) from the neomycin phosphotransferase II (neomycin resistance gene, neo). 62 T-cell stimulation was measured after 24 h of coincubation by determining the specific release of GM-CSF by ELISA (R&D Systems).
FACS analysis
For phenotyping of mature DCs, the cells were washed with PBS and incubated with fluorochrome-coupled monoclonal antibodies directed against CD83(-FITC), CD14(-PE), CD80(-FITC) (Pharmingen), and the respective isotype controls on ice for 20 min. Cell samples were washed and subjected to three-parameter analysis using a FACS machine (FACSCalibur, Becton Dickinson).
ELISA quantification
Cytokine ELISAs were performed essentially as described. 62 For detection of GM-CSF after gene transfer into B cells, 100 ml of cell supernatant was diluted and the amount of cytokine determined by ELISA (R&D Systems). T-cell stimulation was determined after coculture of 1 Â 10 4 DCs and 1 Â 10 5 T cells in 96-well flat-bottom plates containing 200 ml T-cell medium for 24 h. 62 Values shown are the means of duplicates.
Endocytosis studies
To study the endocytotic capacity of DCs, immature DCs on day 6 were incubated with FITC-conjugated dextran (1 mg/ml final concentration, 77 000 MW, Sigma) for 30 min at 371C or 41C. DCs were plated at 5 Â 10 5 cells in 3 ml RPMI1640/10% FCS and supplemented with 100 U/ml IL-4 and 1000 U/ml recombinant GM-CSF or the same amount of gene-vector-derived GM-CSF. The cells were washed three times in ice-cold PBS/2% FCS and analyzed by flow cytometry. The mean fluorescence intensity (MFI) value indicates the difference between FITC-conjugated dextran uptake at 37 versus 41C.
T-cell stimulation
To analyze the DC-mediated T-cell response, 1 Â 10 5
CD19
+ cells were isolated from PBMC via MACS selection with an anti-CD19 antibody (Miltenyi Biotech, Germany), which yielded 495% CD19 + cells. B cells were transduced with the GM-CSF-EBV vectors at an MOI of 0.5 GRU for 24 h and washed thoroughly. After 48 h, CD19 + -depleted PBMCs were added at a ratio of 1:3. After 7 days, PBMCs are restimulated with GM-CSF-EBV vector-transduced CD19 + B cells. The last restimulation was conducted on day 13 for another 16 h, after which the T-cell stimulation was measured by IFN-g capture assay.
IFN-g secretion assay
After 18-24 h of stimulation, mixed PBMCs were washed in cold PBS, the cell pellet resuspended in cold medium and stained with IFN-g Catch Reagent (Miltenyi Biotech). After 10 min, prewarmed medium was added and cells were incubated at 371C for about 1 h while softly agitating to avoid cell-cell contact. Cells were then washed again and counterstained with IFN-g detection reagent (Miltenyi Biotech) and anti-CD3-APC (Pharmingen). Dead cells were excluded by propidium iodine staining. The diagrams in Figure 5 show the percentage of IFN-g/CD3 + double-positive cells.
